Mycosis fungoides in a patient with ulcerative colitis on anti-tumor necrosis factor-alpha therapy-Reference-Cited by-同舟云学术

Mycosis fungoides in a patient with ulcerative colitis on anti-tumor necrosis factor-alpha therapy

Published:2020-11-21 Issue:1 Volume:14 Page:170-175
ISSN:1865-7257
Container-title:Clinical Journal of Gastroenterology
language:en
Short-container-title:Clin J Gastroenterol

Author:

Yasuda Takeshi,Takagi Tomohisa,Asai Jun,Katoh Norito,Kuroda Junya,Kuwahara Yasumichi,Morinaga Yukiko,Konishi Eiichi,Uchiyama Kazuhiko,Naito Yuji,Itoh Yoshito

Publisher

Springer Science and Business Media LLC

Subject

Gastroenterology,General Medicine

Link

http://link.springer.com/content/pdf/10.1007/s12328-020-01277-3.pdf

Reference24 articles.

1. Ng WK, Wong SH, Ng SC. Changing epidemiological trends of inflammatory bowel disease in Asia. Intest Res. 2016;14:111–9.

2. Ooi CJ, Hilmi I, Banerjee R, et al. Best practices on immunomodulators and biologic agents for ulcerative colitis and Crohn’s disease in Asia. Intest Res. 2019;17:285–310.

3. Kandiel A, Fraser AG, Korelitz BI, et al. Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine. Gut. 2005;54:1121–5.

4. Yang C, Huang J, Huang X, et al. Risk of lymphoma in patients with inflammatory bowel disease treated with anti-tumour necrosis factor alpha agents: a systematic review and meta-analysis. J Crohns Colitis. 2018;12:1042–52.

5. Deepak P, Sifuentes H, Sherid M, et al. T-cell non-Hodgkin’s lymphomas reported to the FDA AERS with tumor necrosis factor-alpha (TNF-alpha) inhibitors: results of the REFURBISH study. Am J Gastroenterol. 2013;108:99–105.

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Increased Risk of Cutaneous T‐Cell Lymphoma Development after Dupilumab Use for Atopic Dermatitis;Dermatologic Therapy;2024-01

2. Development of Cutaneous T-Cell Lymphoma Following Biologic Treatment: A Systematic Review;American Journal of Clinical Dermatology;2023-01-10

3. Azathioprine/infliximab/prednisolone;Reactions Weekly;2021-03